Suven secures European patent on SUVN-502

Suven Life Sciences, a biopharmaceutical company based here, has secured a product patent EP 1581492 from the European Patent Office (EPO) for its clinical candidate SUVN-502, valid until June 2023. The product is being developed for central nervous system (CNS) disorders. It can be used in the treatment of cognitive impairments associated with neuro-degenerative disorders such as Alzheimer's disease and attention-deficit hyperactivity disorder or memory loss associated with aging and schizophrenia.